ORCHESTRA BIOMED HOLDINGS IN (OBIO) Stock Price, Quote, News and Overview
NASDAQ:OBIO - Nasdaq - US68572M1062 - Common Stock - Currency: USD
OBIO Quote, Performance and Key Statistics
3.34
0 (0%)
The current stock price of OBIO is 3.34 USD. In the past month the price increased by 26.04%. In the past year, price decreased by -58.09%.
OBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.06 | 233.36B | ||
| ISRG | INTUITIVE SURGICAL INC | 69.32 | 189.82B | ||
| SYK | STRYKER CORP | 30.73 | 147.15B | ||
| BSX | BOSTON SCIENTIFIC CORP | 36.79 | 146.97B | ||
| MDT | MEDTRONIC PLC | 15.99 | 112.81B | ||
| BDX | BECTON DICKINSON AND CO | 12.38 | 49.98B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.15 | 44.46B | ||
| IDXX | IDEXX LABORATORIES INC | 46.13 | 42.62B | ||
| RMD | RESMED INC | 27.83 | 37.05B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.07 | 33.85B | ||
| DXCM | DEXCOM INC | 51.41 | 33.26B | ||
| STE | STERIS PLC | 25.95 | 23.81B |
Related stock screener links
About OBIO
Company Profile
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania and currently employs 70 full-time employees. The company went IPO on 2020-08-04. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. The company is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The company is developing bioelectronic therapies based on patented CNT technology. BackBeat CNT, also known as Atrioventricular Interval Modulation (AVIM) therapy, is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Company Info
ORCHESTRA BIOMED HOLDINGS IN
150 Union Square Drive
New Hope PENNSYLVANIA US
Employees: 56
Phone: 16463439298
ORCHESTRA BIOMED HOLDINGS IN / OBIO FAQ
What is the stock price of ORCHESTRA BIOMED HOLDINGS IN today?
The current stock price of OBIO is 3.34 USD.
What is the ticker symbol for ORCHESTRA BIOMED HOLDINGS IN stock?
The exchange symbol of ORCHESTRA BIOMED HOLDINGS IN is OBIO and it is listed on the Nasdaq exchange.
On which exchange is OBIO stock listed?
OBIO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ORCHESTRA BIOMED HOLDINGS IN stock?
13 analysts have analysed OBIO and the average price target is 13.84 USD. This implies a price increase of 314.46% is expected in the next year compared to the current price of 3.34. Check the ORCHESTRA BIOMED HOLDINGS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ORCHESTRA BIOMED HOLDINGS IN worth?
ORCHESTRA BIOMED HOLDINGS IN (OBIO) has a market capitalization of 127.96M USD. This makes OBIO a Micro Cap stock.
How many employees does ORCHESTRA BIOMED HOLDINGS IN have?
ORCHESTRA BIOMED HOLDINGS IN (OBIO) currently has 56 employees.
What are the support and resistance levels for ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock?
ORCHESTRA BIOMED HOLDINGS IN (OBIO) has a support level at 2.99 and a resistance level at 3.35. Check the full technical report for a detailed analysis of OBIO support and resistance levels.
Is ORCHESTRA BIOMED HOLDINGS IN (OBIO) expected to grow?
The Revenue of ORCHESTRA BIOMED HOLDINGS IN (OBIO) is expected to grow by 1.24% in the next year. Check the estimates tab for more information on the OBIO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OBIO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OBIO, evaluating the profitability, health, valuation and growth aspects
- ORCHESTRA BIOMED HOLDINGS IN (OBIO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ORCHESTRA BIOMED HOLDINGS IN (OBIO) Sales and EPS estimates to see what analysts future expectations are.
- ORCHESTRA BIOMED HOLDINGS IN (OBIO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ORCHESTRA BIOMED HOLDINGS IN (OBIO) Insider and Institutional Ownership to learn about the owners and their transactions.
- ORCHESTRA BIOMED HOLDINGS IN (OBIO) Stock Chart to make your own analysis
- ORCHESTRA BIOMED HOLDINGS IN (OBIO) Latest news and press-releases to stay up to date.
Does ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock pay dividends?
OBIO does not pay a dividend.
What is the Price/Earnings (PE) ratio of ORCHESTRA BIOMED HOLDINGS IN (OBIO)?
ORCHESTRA BIOMED HOLDINGS IN (OBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.77).
What is the Short Interest ratio of ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock?
The outstanding short interest for ORCHESTRA BIOMED HOLDINGS IN (OBIO) is 4.71% of its float. Check the ownership tab for more information on the OBIO short interest.
OBIO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to OBIO. When comparing the yearly performance of all stocks, OBIO is a bad performer in the overall market: 94.06% of all stocks are doing better.
OBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OBIO. OBIO may be in some trouble as it scores bad on both profitability and health.
OBIO Financial Highlights
Over the last trailing twelve months OBIO reported a non-GAAP Earnings per Share(EPS) of -1.77. The EPS decreased by -19.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -112.3% | ||
| ROE | -393.4% | ||
| Debt/Equity | 0.85 |
OBIO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to OBIO. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -22.99% and a revenue growth 1.24% for OBIO